Free Trial
NYSE:GRDN

Guardian Pharmacy Services (GRDN) Stock Price, News & Analysis

Guardian Pharmacy Services logo
$36.60 +0.34 (+0.92%)
As of 12:10 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Guardian Pharmacy Services Stock (NYSE:GRDN)

Advanced

Key Stats

Today's Range
$35.93
$37.35
50-Day Range
$31.88
$40.60
52-Week Range
$19.17
$41.36
Volume
114,703 shs
Average Volume
378,506 shs
Market Capitalization
$2.32 billion
P/E Ratio
44.11
Dividend Yield
N/A
Price Target
$41.33
Consensus Rating
Buy

Company Overview

Guardian Pharmacy Services Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
67th Percentile Overall Score

GRDN MarketRank™: 

Guardian Pharmacy Services scored higher than 67% of companies evaluated by MarketBeat, and ranked 195th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Guardian Pharmacy Services has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 7 buy ratings, 1 hold rating, and no sell ratings.

  • Upside Potential

    Guardian Pharmacy Services has a consensus price target of $41.33, representing about 14.8% upside from its current price of $36.01.

  • Amount of Analyst Coverage

    Guardian Pharmacy Services has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Guardian Pharmacy Services' stock forecast and price target.
  • Earnings Growth

    Earnings for Guardian Pharmacy Services are expected to grow by 10.26% in the coming year, from $1.17 to $1.29 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Guardian Pharmacy Services is 43.38, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.37.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Guardian Pharmacy Services is 43.38, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.45.

  • Price to Earnings Growth Ratio

    Guardian Pharmacy Services has a PEG Ratio of 2.43. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Guardian Pharmacy Services has a P/B Ratio of 10.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    5.94% of the float of Guardian Pharmacy Services has been sold short.
  • Short Interest Ratio / Days to Cover

    Guardian Pharmacy Services has a short interest ratio ("days to cover") of 4.73.
  • Change versus previous month

    Short interest in Guardian Pharmacy Services has recently decreased by 13.54%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Guardian Pharmacy Services does not currently pay a dividend.

  • Dividend Growth

    Guardian Pharmacy Services does not have a long track record of dividend growth.

  • News Sentiment

    Guardian Pharmacy Services has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Guardian Pharmacy Services this week, compared to 2 articles on an average week.
  • Search Interest

    9 people have searched for GRDN on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Guardian Pharmacy Services insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $288,679,700.00 in company stock.

  • Percentage Held by Insiders

    32.96% of the stock of Guardian Pharmacy Services is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Guardian Pharmacy Services has minimal institutional ownership at this time.

  • Read more about Guardian Pharmacy Services' insider trading history.
Receive GRDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Guardian Pharmacy Services and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GRDN Stock News Headlines

I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.tc pixel
Guardian (GRDN) Q1 2026 Earnings Transcript
See More Headlines

GRDN Stock Analysis - Frequently Asked Questions

Guardian Pharmacy Services' stock was trading at $30.01 at the beginning of 2026. Since then, GRDN stock has increased by 21.8% and is now trading at $36.5650.

Guardian Pharmacy Services, Inc. (NYSE:GRDN) announced its quarterly earnings results on Wednesday, May, 6th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.24 by $0.05. The company's quarterly revenue was up 2.2% on a year-over-year basis.
Read the conference call transcript
.

Guardian Pharmacy Services (GRDN) raised $102 million in an initial public offering on Thursday, September 26th 2024. The company issued 6,800,000 shares at a price of $14.00-$16.00 per share. Raymond James, Stifel and Truist Securities acted as the underwriters for the IPO.

Guardian Pharmacy Services' top institutional investors include Jennison Associates LLC (1.30%), Dimensional Fund Advisors LP (0.33%), Peregrine Capital Management LLC (0.32%) and Allspring Global Investments Holdings LLC (0.21%). Insiders that own company stock include William E Bindley, Thomas J Salentine Jr, Fred Burke, Kendall Forbes, John Ackerman, Equity Fund LP Cardinal, David K Morris and Steven D Cosler.
View institutional ownership trends
.

Shares of GRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Guardian Pharmacy Services investors own include UnitedHealth Group (UNH) and Meta Platforms (META).

Company Calendar

Last Earnings
5/06/2026
Today
5/08/2026
Bank of America Global Healthcare Conference 2026
5/13/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Retail
Current Symbol
NYSE:GRDN
Previous Symbol
NYSE:GRDN
CIK
1802255
Fax
N/A
Employees
3,600
Year Founded
2004

Price Target and Rating

High Price Target
$44.00
Low Price Target
$36.00
Potential Upside/Downside
+13.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.77
Trailing P/E Ratio
44.10
Forward P/E Ratio
31.25
P/E Growth
2.43
Net Income
$49.22 million
Net Margins
3.64%
Pretax Margin
5.07%
Return on Equity
32.07%
Return on Assets
16.41%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.38
Quick Ratio
1.11

Sales & Book Value

Annual Sales
$1.45 billion
Price / Sales
1.60
Cash Flow
$1.26 per share
Price / Cash Flow
29.04
Book Value
$3.44 per share
Price / Book
10.63

Miscellaneous

Outstanding Shares
63,320,000
Free Float
42,450,000
Market Cap
$2.32 billion
Optionable
N/A
Beta
0.09

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NYSE:GRDN) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners